Biotech Values

[DewDiligence]

KITE, BLUE ink drug-discovery collaboration for TCR products targeted to HPV-mediated cancers:

http://finance.yahoo.com/news/kite-pharma-bluebird-bio-announce-120000822.html

…both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells.

Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, including research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.

Other financial details have not been disclosed.

KITE has an Investor Day webcast tomorrow (#msg-114639751).